Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals Inc.

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Regeneron, with a price target of $825.00. Bansal covers the ...

Wells Fargo Sticks to Its Hold Rating for Regeneron (REGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medios AG (MEDOF), Regeneron (REGN) and Siemens Heal...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released on March 20, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron, with a price target of $967.00. The comp...

Regeneron (REGN) Receives a Buy from Goldman Sachs

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Electrocore (ECOR) and Regeneron (REGN) with bullish...

Analysts Offer Insights on Healthcare Companies: Electrocore (ECOR) and Regeneron (REGN)

Friday may be a volatile day for the S&P 500 (SPX) and the Nasdaq 100 (NDX), as $5.7 trillion worth of options tied to individual U.S. stocks, inde...

Get Ready for a $5.7 Trillion ‘Triple-Witching’ Event on Friday

Regeneron Pharmaceuticals ($REGN), Sanofi SA ($SNY) announced an update on their ongoing clinical study. The Impact of Dupilumab Treatment on Anxie...

Dupilumab Study Tracks Mental Health Benefits in Atopic Dermatitis Patients Across Gulf Countries

Jefferies analyst Akash Tewari maintained a Buy rating on Regeneron today and set a price target of $890.00. Tewari covers the Healthcare sector, f...

Current Quarter	$6.15	Next Quarter	$8.08
Current Year	$35.31	Next Year	$40.97
QoQ Growth	+31.4%	YoY Growth	+16.0%
3Y EPS CAGR	-18.8%	Target Price	$873.57
Consensus	Buy	Upside	+13.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$767.85	-0.99%	594.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$767.85	-1.0%	594.46K
3
4
5
6

REGN

REGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Regeneron Pharmaceuticals Inc. Data in Excel

Get Regeneron Pharmaceuticals Inc. Data in Excel